Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study-Reference-Cited by-同舟云学术

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Published:2016-02 Issue:10019 Volume:387 Page:679-690
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Armstrong Matthew James,Gaunt Piers,Aithal Guruprasad P,Barton Darren,Hull Diana,Parker Richard,Hazlehurst Jonathan M,Guo Kathy,Abouda George,Aldersley Mark A,Stocken Deborah,Gough Stephen C,Tomlinson Jeremy W,Brown Rachel M,Hübscher Stefan G,Newsome Philip N

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States;Charlton;Gastroenterology,2011

2. Extra-hepatic complications of nonalcoholic fatty liver disease;Armstrong;Hepatology,2014

3. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality;Younossi;Hepatology,2011

4. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up;Ekstedt;Hepatology,2015

5. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

Cited by 1523 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11

3. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

5. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13